Sanofi announces today the closing of the sale to CD&R of a 50.0% controlling stake of its consumer healthcare business Opella. Sanofi retains a significant shareholding of Opella with a 48.2% stake.

American buyout firm Clayton, Dubilier & Rice (CD&R), a strategic partner to homegrown private equity firm Kedaara Capital, is moving forward with the India leg of a multi-billion-dollar global deal ...

NEW YORK, April 8, 2025 /PRNewswire/ -- CD&R (or the "Firm") announced today the appointment of Michael Harrington as Risk Director, a newly created position that will provide strategic risk ...

NEW YORK, March 31, 2025 /PRNewswire/ -- CD&R (or the "Firm") today announced the appointment of Walt Bettinger, former chief executive of The Charles Schwab Corporation ("Schwab"), as Senior ...

However, current equity investors might see massive dilution from the CD&R convertible equity investment ... "Value in Corporate Events" here and try the free trial. In this service we cover ...

It is currently optimised for use with Optical Disc Emulators, which replace the Dreamcast's optical drive, but it is possible to play from a burnt CD-R though ... if you try to use the ...

“Early in Morrisons ownership by CD&R interest rates sharply rose and so ... “It cut too much labour out and allowed its price file to rise to try and protect profits to cover debt costs.” ...

Always test each package of CD-Rs by choosing a CD-R at random and recording and then retrieving the information from the recorded disc to see if that batch of CD-Rs is reliable. If possible, try ...

The field-of-view feels smaller than Quest 3 or Vision Pro, but before I say that definitively, I first need to try different forehead pad options (confirmed to be included) which may be able to ...

(Bloomberg) -- Vialto Partners, a provider of tax and immigration services, has agreed to restructure its debt a little more than two years after the company spun out of PricewaterhouseCoopers and ...

A group including CD&R and existing lenders, including HPS Investment Partners, agreed to a deal that will inject $225 million of new equity into Vialto and slash around $700 million of its ...

The deal would allow Sanofi to focus on its more lucrative, but riskier, innovative drugs and vaccines, and CD&R to take a 50% controlling stake in a business that is home to brands such as ...